AbbVie stock is getting attention after the FDA gave special approval for its new cancer drug.

Oct 7, 2026, 10:59 PM ETTrialRead the original at Benzinga

Good for ABBV

AbbVie received 2 FDA special designations for its cancer drug, which may speed its development and review. The drug is still being tested and is not approved, so any benefit remains uncertain.

ABBV · AbbVie Inc.

AI read · Good for ABBV

The AI's read

This gives AbbVie a possible faster route to develop its cancer drug. The designations cover 2 cancer settings, and the company is also studying the drug in other cancers. The news is encouraging, but the designations were based mainly on an early study, and the drug is not approved.

Get alerts for ABBV

Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABBV

Free on the App Store and Google Play, or on the web.